PURPOSE: We hypothesized that inducibility of the VT responsible for ICD therapies at the end of RFCA, would also be associated with a differential risk, depending on left ventricular function. METHODS: We retrospectively studied 66 patients with previous myocardial infarction and with ICD who also underwent RFCA for recurrent refractory VTs. RESULTS: During the follow-up only 19 patients (29%) showed VTs. Among patients with ejection fraction (EF) <or= 35%, 11 out of 25 still continued to have VT recurrences, independent of the inducibility of the VT. Among patients with EF >35% and <50%, no recurrent VT was any longer detected in the nine patients in whom the VT was not inducible, while VT recurrences still continued only in the eight patients in whom it was. Finally, all the 24 patients with EF >or=50% did not show any recurrent VT. CONCLUSIONS: Our findings confirm the role of RFCA in reducing ICD therapies and also place RFCA in the overall clinical management of recurrent post infarction VTs according to the left ventricular function.
PURPOSE: We hypothesized that inducibility of the VT responsible for ICD therapies at the end of RFCA, would also be associated with a differential risk, depending on left ventricular function. METHODS: We retrospectively studied 66 patients with previous myocardial infarction and with ICD who also underwent RFCA for recurrent refractory VTs. RESULTS: During the follow-up only 19 patients (29%) showed VTs. Among patients with ejection fraction (EF) <or= 35%, 11 out of 25 still continued to have VT recurrences, independent of the inducibility of the VT. Among patients with EF >35% and <50%, no recurrent VT was any longer detected in the nine patients in whom the VT was not inducible, while VT recurrences still continued only in the eight patients in whom it was. Finally, all the 24 patients with EF >or=50% did not show any recurrent VT. CONCLUSIONS: Our findings confirm the role of RFCA in reducing ICD therapies and also place RFCA in the overall clinical management of recurrent post infarction VTs according to the left ventricular function.
Authors: Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip Journal: N Engl J Med Date: 2005-01-20 Impact factor: 91.245
Authors: A Pacifico; S H Hohnloser; J H Williams; B Tao; S Saksena; P D Henry; E N Prystowsky Journal: N Engl J Med Date: 1999-06-17 Impact factor: 91.245
Authors: M J Domanski; S Sakseena; A E Epstein; A P Hallstrom; M A Brodsky; S Kim; S Lancaster; E Schron Journal: J Am Coll Cardiol Date: 1999-10 Impact factor: 24.094
Authors: Arthur J Moss; Henry Greenberg; Robert B Case; Wojciech Zareba; W Jackson Hall; Mary W Brown; James P Daubert; Scott McNitt; Mark L Andrews; Adam D Elkin Journal: Circulation Date: 2004-12-06 Impact factor: 29.690
Authors: Stuart J Connolly; Paul Dorian; Robin S Roberts; Michael Gent; Steven Bailin; Eric S Fain; Kevin Thorpe; Jean Champagne; Mario Talajic; Benoit Coutu; Gerian C Gronefeld; Stefan H Hohnloser Journal: JAMA Date: 2006-01-11 Impact factor: 56.272